LFB-SA
18.4.2016 15:39:14 CEST | Business Wire | Press release
Key events in 2015 :
- Launched a new generation plant financed by a €230 million capital increase, fully underwritten by the French State, currently the sole shareholder of LFB.
- Two new products registered in Europe
- Significant investment in R&D with €81.3 million* owing to several products currently in phase III trials
- Gross margin in decline as compared to 2014 due to the production of commercial batches for phase III products
- Turnover of €502.4 million, stable in comparison to 2014
Christian Béchon, Chief Executive Officer of L.F.B S.A. declared:
"In
2015, the key milestones have been successfully achieved. It has been a
historic and productive year for the future of LFB."
An unprecedented increase in capital in order to finance the group's
development
As part of the group's strategic development, LFB's
shareholder (the French State) decided in October to underwrite an
increase in LFB's share capital by €230 million. The share capital of
the company now stands at €280 million. To meet the financing needs of
LFB's development project, on 5 January 2016 LFB issued a senior bond of
€124 million. These funds will enable the construction of a 'new
generation' plant in Arras. This flagship project, representing an
investment of approximately €300 million, will enable LFB to triple its
global production capacity in 2020 with facilities aimed at
manufacturing for the whole world.
LFB is also developing its sites
in Alès (Gard) and Charlton (USA), establishing bio-production
facilities for recombinant medicines in development.
|
Consolidated earnings in €M |
2015 | 2014 | Variation 2015/2014 | |||
|
Turnover |
502.4 |
501.9 |
0.1 % |
|||
|
Gross margin |
177.6 |
195.5 |
-9.2 % |
|||
|
Research & development |
(81.3) |
(65.9) |
||||
|
Commercial costs |
(51.0) |
(48.6) |
||||
|
General costs |
(50.3) |
(48.7) |
||||
|
Other charges and |
17.0 |
(7.1) |
||||
|
Operational earnings |
12.0 |
25.2 |
||||
|
as a % of turnover |
2.4 % |
5.0 % |
||||
|
Net earnings |
0.3 |
13 |
€90.5 million* before research tax credit
2015 turnover - growth in international sales
At €502.4
million, turnover is relatively stable as compared to 2014. For the
second successive year, the group's turnover exceeded €500 million, with
the international side business continuing to grow. Despite a 3.2 %
decline in turnover in France during 2015, international sales rose by
€12.1 million (+8.7%), reaching €152 million. This figure represents 30%
of consolidated turnover (28% in 2014).
Operational earnings decline in order to finance strategy
Research
and development costs are increasing rapidly (€81.3 million), owing to
the large number of phase III trials in progress. Various strategic
projects reached significant milestones. In 2015, two new LFB products,
a 10% immunoglobulin and a fibrinogen have been subject to a mutual
recognition in procedure in Europe with the Paul Ehrlich Institute as
the referral agency. Two other recombinant products are currently at the
end of phase III. At the same time, LFB is planning to manufacture
product batches for launch, which has had an impact on earnings. In
2015, the group posted encouraging operational income (€17 million),
notably owing to its holding in the bio-tech company TG Therapeutics
Inc. The positive operational earnings (€12.0 million) is down as
compared to that of 2014 (-13.2 million) due to a decline in gross
margins and increased development costs. Despite this unprecedented
effort, net earnings remain positive at €0.3 million.
About LFB Group
LFB is a
bio-pharmaceutical company that develops, manufactures, and markets
medicinal products from living systems for the treatment of serious and
often rare diseases in the fields of Immunology, Hemostasis, Perinatal,
and Intensive Care. Currently ranked 6th worldwide in the field of
plasma-derived medicinal products, LFB Group is also among the leading
European companies in the development and production of proteins and
innovative treatments derived from bio-technologies. It employs 2,111
staff worldwide.
http://www.groupe-lfb.fr
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160418005971/en/
Contact:
LFB SA
Sandrine Charrières, 01.69.82.72.80
Communication
Director
charrieres@lfb.fr
or
David
Loison, 01.69.82.70.20
Financial Affairs Director
loisond@lfb.fr
or
Havas
Worldwide
Jeanne Bariller, 06.15.51.49.40
jeanne.bariller@havasww.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet HaystackID29.1.2026 21:20:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for cybersikkerhed og teknologi gennem en samarbejdsaftale med HaystackID, en amerikansk udbyder af eDiscovery, juridiske data og cyber discovery-tjenester. HaystackID blev stiftet i 2011 og arbejder tæt sammen med advokatfirmaer, virksomheder og offentlige myndigheder om at håndtere komplekse, dataintensive juridiske sager, herunder civile retssager, myndighedsundersøgelser og interne undersøgelser. Firmaet leverer komplet processtøtte ved hjælp af cyber discovery, digital efterforskning, managed review, compliance og information governance, hvilket hjælper klienter med at identificere, analysere og forsvarligt fremlægge kritiske data. Ved hjælp af proprietære ai-drevne platforme og ekspertledede reviewteams betjener HaystackID klienter i hele Nordamerika og Europa, heriblandt Fortune 100-virksomheder. "I takt med at de juridiske og regulatoriske miljøer bliver mere datadrevne og tidskritiske, fortsætter vi med at udvikle vores kompet
Convera Appoints Industry Leader Meaghan Riley as Chief Commercial Officer to Scale Commercial Growth and Expand Revenue Opportunities29.1.2026 17:14:00 CET | Press release
Former Google Cloud and SAP executive will build on Convera’s success and leadership in the commercial payments sector Convera, a global leader in commercial payments, today announces the appointment of Meaghan Riley to Chief Commercial Officer, as the company continues its growth trajectory, expands to new markets, and drives scalable revenue opportunities across geographies and sectors. Prior to Convera, Meaghan was Chief Operating Officer for Google Cloud North America, where she led a major go-to-market transformation and launched high-growth segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129799440/en/ Meaghan Riley, Chief Commercial Officer, Convera “Meaghan’s impressive career journey and proven track record brings exceptional experience and unique assets that will strengthen our leadership team at this pivotal moment in Convera’s journey,” said Patrick Gauthier, CEO, Convera. “Meaghan’s leadership will be
New Year, New Solutions: AMRA Medical Continues Commitment to Innovation & Data-Driven Excellence29.1.2026 16:23:00 CET | Press release
AMRA Medical, the global leader in MRI-based fat distribution and muscle composition analytics, is excited to share our brand repositioning supported by the launch of a refreshed website and the introduction of a new tagline, “Insights Within.” This strategic update reflects AMRA’s commitment to placing clients and collaborators at the center of our vision: to be the most trusted, insights-driven imaging partner in the pursuit of preventing and curing disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129457626/en/ The new website provides a more structured and transparent presentation of AMRA’s biomarkers and research services, enabling our partners to have a clear understanding of our offerings, as well as the scientific value and applications of these solutions. For the first time, we’re introducing Imaging Biomarkers and Insights Biomarkers: clearly-defined, intentional offerings that are designed with your trial
NTT DATA Signs Strategic Collaboration Agreement with AWS to Accelerate Enterprise Cloud and Agentic AI Adoption29.1.2026 14:00:00 CET | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced a multi-year Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to help enterprises modernize legacy systems, adopt agentic AI responsibly and scale innovation across industries. Combining NTT DATA’s expertise in cloud transformation, cloud-native modernization and Agentic AI with the scale and innovation velocity of AWS services, the collaboration will deliver tailored enterprise solutions that modernize mission-critical workloads, build secure cloud foundations and drive measurable business outcomes across regulated and high-growth industries. Under the agreement, NTT DATA and AWS will accelerate enterprise transformation in four priority areas: AI-driven large-scale cloud transformation: Accelerating the migration and modernization of on-premises workloads on AWS, leveraging generative and agentic AI, automation and data platforms to unlock new business models and drive int
U.S. Department of Energy and Kyoto Fusioneering Launch Strategic Partnership to Build Critical Fusion Infrastructure and Accelerate Deployment of Commercial Fusion Power29.1.2026 14:00:00 CET | Press release
Today, the U.S. Department of Energy (DOE) and Kyoto Fusioneering (KF) established a landmark partnership to deliver critical fusion infrastructure and perform collaborative R&D to drive down technology and commercialization risk. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127164854/en/ Anchored by a new public-private partnership between KF and Oak Ridge National Laboratory (ORNL) that leverages each institution’s expertise in fusion technology to develop world-leading fusion test facilities and technology, this agreement establishes a new paradigm in U.S.-Japan allied cooperation and public-private partnership towards accelerating the deployment of commercial fusion power. Under the new partnership, KF and ORNL will commence joint research and development activities focused on fusion breeding blanket systems, a critical technology for producing the tritium fuel needed to sustain fusion power generation. This include
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
